Omnicell Inc (OMCL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Omnicell Inc stock (OMCL) is currently trading at $34.94. Omnicell Inc PE ratio is 861.50. Omnicell Inc PS ratio (Price-to-Sales) is 1.32. Analyst consensus price target for OMCL is $57.43. WallStSmart rates OMCL as Sell.
- OMCL PE ratio analysis and historical PE chart
- OMCL PS ratio (Price-to-Sales) history and trend
- OMCL intrinsic value — DCF, Graham Number, EPV models
- OMCL stock price prediction 2025 2026 2027 2028 2029 2030
- OMCL fair value vs current price
- OMCL insider transactions and insider buying
- Is OMCL undervalued or overvalued?
- Omnicell Inc financial analysis — revenue, earnings, cash flow
- OMCL Piotroski F-Score and Altman Z-Score
- OMCL analyst price target and Smart Rating
Omnicell Inc
📊 No data available
Try selecting a different time range
OMCL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Omnicell Inc (OMCL)
OMCL trades 13907% above its Graham fair value of $0.27, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Omnicell Inc (OMCL) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Omnicell Inc (OMCL) Key Strengths (3)
105.57% of shares held by major funds and institutions
Paying $1.32 for every $1 of annual revenue
Trading at 1.22x book value, attractively priced
Supporting Valuation Data
Omnicell Inc (OMCL) Areas to Watch (7)
Earnings declining -35.90%, profits shrinking
Very low returns on shareholder equity
Near-zero operating margins, business under pressure
Very expensive relative to growth, significant premium
Revenue growing slowly at 2.30% annually
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Omnicell Inc (OMCL) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.7/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.32), Price/Book (1.22) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (15.40) suggest expensive pricing. Growth concerns include Revenue Growth at 2.30%, EPS Growth at -35.90%, which may limit upside. Profitability pressure is visible in Return on Equity at 0.17%, Operating Margin at 2.20%, Profit Margin at 0.17%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 0.17% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. EPS Growth and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OMCL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OMCL's Price-to-Sales ratio of 1.32x sits near its historical average of 1.43x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 18% below its historical high of 1.61x set in Mar 2026, and 4% above its historical low of 1.27x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.6x as trailing revenue scaled faster than the stock price.
Compare OMCL with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Omnicell Inc (OMCL) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Omnicell Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.2B with 230% growth year-over-year. Profit margins of 17.0% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 230% YoY, reaching 1.2B. This pace significantly outperforms most HEALTH INFORMATION SERVICES peers.
Generating 20M in free cash flow and 30M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Omnicell Inc maintain 230%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 861.5x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Omnicell Inc.
Bottom Line
Omnicell Inc offers an attractive blend of growth (230% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Omnicell Inc(OMCL)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.